Royalty Report: Drugs, Disease, Therapeutic – Collection: 201028

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Wound Care
  • Blood Clotting
  • Drug Discovery
  • Biotechnology
  • Cancer
  • Surgical
  • cardiac
  • Pharmaceuticals
  • Pain
  • Genome

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 201028

License Grant
The development and commercialization agreement is to develop and commercialize ELOCTATE and ALPROLIX globally.  Each party have specific territories.
License Property
ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], are extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor, thereby making the product last longer in a persons blood than traditional factor therapies.
Field of Use
The agreement is for the drug industry, specifically for clotting-factor therapies.

Elocta is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein.

IPSCIO Record ID: 185232

License Grant
The development and commercialization agreement is to develop and commercialize ELOCTATE and ALPROLIX globally.  Each party has specific territories.
License Property
ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], are extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor, thereby making the product last longer in a persons blood than traditional factor therapies.
Field of Use
The agreement is for the drug industry, specifically for clotting-factor therapies.

IPSCIO Record ID: 74387

License Grant
In this cross license agreement the Licensor grants the Swedish Licensee the exclusive, except as to Licensor and its affiliates and permitted sublicensees
worldwide license under the Licensor's IP and interest in the Jointly-Owned IP to Develop Products and to engage in Post Opt-In Development with respect to Products for which Licensee has Opted-In;  
the exclusive,  worldwide license under theLicensor's IP and interest in the Jointly-Owned IP to Manufacture, limited to fill-finish and/or pack and label of commercial Product, the Products;
and the exclusive, except, with respect to Finalization, as to Licensor and its Affiliates prior to Licensee’s exercise of the Opt-In Right for the applicable Product, license under the Licensor's IP and interest in the Jointly-Owned IP to Finalize and, following Opt-In for such Products, to Commercialize the Products in the Licensee's Territory.  Licensee may sublicense the rights granted.
License Property
ELOCTATEâ„¢ [Antihemophilic Factor (Recombinant), Fc Fusion Protein] Control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A

ALPROLIXâ„¢ [Coagulation Factor IX (Recombinant), Fc Fusion Protein] Control and prevention of bleeding episodes, perioperative management and routine prophylaxis in adults and children with hemophilia B

Factor VIIIFc Construct means a construct that includes the Fc portion of an immunoglobulin fused to Factor VIII or a derivative of Factor VIII.   Factor IXFc Construct means a construct that includes the/ Fc portion of an immunoglobulin fused to Factor IX or a derivative of Factor IX.

IPSCIO Record ID: 369275

License Grant
Korean Licensor hereby grants to Licensee, after the Phase I Development Period, an exclusive, sublicenseable, royalty-bearing license, under the Licensor Technology, to conduct Clinical Development and Manufacturing Development, to Manufacture and to Commercialize Products in the Field in the Territory. Licensee shall not, and shall not permit any of its Affiliates or sublicensees to, use or practice any Licensor Technology outside the scope of the license granted to it under this Agreement.
License Property
Product means any product containing any Compound, including the Lead Candidate.

Compound means Licensees CB 2679d and Licensees other novel variants of human factor IX ('FIX'), defined in the Agreement whether in existence as of the Effective Date or anytime thereafter during the Term.

Lead Candidate means any Product containing the Licensees FIX variant CB 2679d Compound or, any replacement Compound selected by the JSC pursuant to this Agreement.

Licensor Technology means the Licensor Know-How and the Licensor Patents.

Field of Use
The Parties have formed a strategic collaboration to develop Licensee's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients.

CB 2679d/ISU 304 is a next-generation Factor IX drug for the on-demand and prophylactic treatment of patients with hemophilia B, a chronic disease caused by a genetic deficiency in coagulation Factor IX.
Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Factor IX is a clotting factor. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing.

CB 2679d/ISU 304 has demonstrated duration of action in vivo in preclinical models of bleeding and coagulation correction approximately 8 times longer than BeneFIX®, the currently marketed Factor IX therapeutic, and 2-3 times longer than Alprolix, Biogen Idec’s approved Factor IX-Fc fusion protein.

IPSCIO Record ID: 263948

License Grant
Licensor grants to the Swiss Licensee a worldwide, exclusive, even as to Licensor, license under the Licensor IP to research, develop, make, have made, use, import, have sold, sell and offer to sell Licensed Products.
License Property
The intellectual property is in respect to Recombinant Factor XIII and related preclinical and clinical studies.

Patent Product means a product that contains Recombinant Factor XIII, the making, using, importation, exportation, offer for sale or sale of which product would infringe, in the absence of the licenses granted under this Agreement, any unexpired Patent Claim.

Recombinant Factor VIIa and rFVIIa mean a protein that has an amino acid sequence of human factor VIIa or its subunits and that is produced by recombinant DNA techniques (including without limitation, production in prokaryotic and eukaryotic host cells and transgenic animals), including variants, derivatives, modifications, fragments, hybrids, mutants, conjugates, fusion proteins and analogs of such protein. Recombinant Factor VIIa and rFVIIa shall mean the active Factor VIIa protein in Licensee’s product known as NovoSeven®.

Recombinant Factor XIII and rFXIII mean a protein that has an amino acid sequence of human factor XIII or its subunits, or any combination thereof, and that is produced by recombinant DNA techniques, including, without limitation, production in prokaryotic and eukaryotic host cells and transgenic animals, including variants, derivatives, modifications, fragments, hybrids, mutants, conjugates, fusion proteins and analogs of such protein.

NovoSeven (coagulation factor viia recombinant) is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues (MW 50 K Dalton). NovoSeven (coagulation factor viia recombinant) is structurally similar to human plasma-derived Factor VIIa.

Field of Use
The field of use is Cancer Treatment or Cardiac Surgery.

Cancer Treatment Indication means bleeding in a patient with malignancy that occurs either as a consequence of the malignancy or the treatment of the malignancy and requires medical intervention.

Cardiac Surgery Indication means bleeding or oozing of blood in a patient undergoing cardiac surgery or having undergone cardiac surgery that occurs during or following the surgery and requires medical intervention.

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for
– Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response to platelet transfusions
– Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

IPSCIO Record ID: 4504

License Grant
The agreement is to develop products with an extended half-life of certain proteins and molecules using the Licensor’s patent protected PolyXen® technology whereby polysialyic acid (“PSA” – a chain of polysialic acids) is chemically conjugated with the Licensee’s proprietary molecule(s) to create a new generation of drugs to treat the failure of blood to coagulate in the therapeutic treatment of blood and bleeding disorders, such as hemophilia. The lead candidate in this collaboration is a longer-acting form of a full length recombinant Factor VIII protein.  Under the terms of the Agreement, the Licensor is entitled to research and development funding and is responsible for providing Licensee with a transfer of the Licensor's proprietary technology and supplying its requirements for PSA.

IPSCIO Record ID: 74377

License Grant
The Swedish Licensor grants the Licensee during the Term, the exclusive, except as to Licensor and its Affiliates and permitted sublicensees,  worldwide license under the IP and interest in the Jointly-Owned IP to Develop the Products and to engage in Post Opt-In Development with respect to Products,  the exclusive, except as to Licensor’s and its Affiliates’ and permitted sublicensees’ rights to Manufacture packaged and labeled finished drug product from drug substance provided by Licensee, worldwide license under the IP and interest in the Jointly-Owned IP to Manufacture the Products, the exclusive, royalty-bearing license under the IP and interest in the Jointly-Owned IP to Finalize and Commercialize the Products in the Licensee's Territory, and the non-exclusive license under the IP and interest in the Jointly-Owned IP to Finalize each Product in the Licensor Territory prior to Licensor's exercise of its Opt-In Right for such Product.  Licensee may sublicense the rights granted.

The agreement is to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX by the Swedish Licensor and Company.  Under the agreement, the cross commercial rights are determined by certain territories.

License Property
ELOCTA® (rFVIIIFc) is for the treatment of hemophilia; Control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A

Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.

IPSCIO Record ID: 3053

License Grant
The Licensee has licensed novel gene integration technology from the Licensor. The Licensee has worldwide commercial rights and all intellectual property rights arising from the technology in all indications in hemophilia and pain management.
License Property
The patented technology proposes to replace daily or weekly protein replacement therapy with a single, lasting procedure that promotes normal blood coagulation. The key is to insert a healthy copy of the human gene for Factor IX, a protein responsible for blood clotting, into the cells of a hemophilia patient. If this method promotes robust, persistent and normal levels of Factor IX, patients may be cured of hemophilia.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 243463

License Grant
The German Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, an exclusive license under the Licensed Patents in the Territory, and in the Field of Use to develop, make, have made, import, have imported, use, offer for sale, sell, have sold and otherwise commercialize Licensed Product(s). For the avoidance of doubt, the exclusive license granted hereby relates solely to Recombinant Factor XIII.
License Property
Licensed Product(s) means any product that contains Recombinant Factor XIII and is covered by a Valid Claim of an issued patent falling within the Licensed Patents or that, but for this Agreement, would infringe a Valid Claim of an issued patent falling within the Licensed Patents.

Recombinant Factor XIII means a protein having the amino acid sequence of naturally occurring factor XIII and that is produced by recombinant DNA techniques, including without limitation production in prokaryotic and eukaryotic host cells and transgenic animals, as well as variants, derivatives, modifications, fragments, hybrids, mutants, conjugates, fusion proteins, analogs, orthologs and homologs thereof.

Licensed Patents
6,084,074 – Stabilized aqueous liquid preparations of blood coagulation factor XIII
6,204,036 – Stable transglutaminase preparations and processes for their production
5,688,919 – Process for the purification of factor XIII, monoclonal antibodies against factor XIIIA, the preparation and use thereof

Field of Use
These include rFactor XIII for the treatment of congenital and acquired Factor XIII deficiencies, recombinant human Thrombin (rhThrombin) as a topical hemostat to control surgical bleeding and TACI-Ig for the treatment of autoimmune diseases including Systemic Lupus Erythematosus.

IPSCIO Record ID: 369407

License Grant
Licensor of Cayman Islands hereby grants to Licensee an exclusive license or sublicense, as the case may be, under the Licensor Technology, solely to develop, make, have made, use, import, offer for sale and sell Licensed Compounds and corresponding Products for use in the Field in the Territory.
License Property
The alliance is to co-develop recombinant factor VIIa products for multiple indications, including intracerebral hemorrhage (ICH) and trauma.
Field of Use
The agreement relates to the development and commercialization of the Licensee’s next generation recombinant factor VIIa product candidates for certain indications, including intracerebral hemorrhage and trauma.

Factor VII is a natural protein with a pivotal role in blood coagulation and clotting. Today, recombinant factor VIIa is approved in the United States and Europe for the treatment of hemophilia.

Field means the prophylaxis, treatment and/or palliation of any human bleeding disorder or injury other than Hemophilia. By way of illustration, but without limitation, the Field includes trauma, intracerebral hemorrhage, thrombocytopenia, cirrhosis/variceal bleeds, and bleeding caused by surgery (including, without limitation, transplant surgery).

IPSCIO Record ID: 237378

License Grant
The License is granted for the purpose of developing, making, using, selling and otherwise disposing of Product.

The Licensor of England grants to the Licensee the following License
(i)  a non-exclusive sub-license under United States Patent 4,994,371 to manufacture or have made for it Products and to use, sell or otherwise dispose of, anywhere in the world, Products made in the United States; and,
(ii)  a non-exclusive license under the other Patents to manufacture or have made for it Products and to use, sell or otherwise dispose of, anywhere in the world, Products made in the countries covered by the aforesaid other Patents.

License Property
The patents are for Factor IX Gene Clone.
Field of Use
The field of use is human recombinant Factor IX protein produced from cell culture.  The Field shall exclude any product, therapy, treatment or procedure in which living material is administered or howsoever brought into contact with the recipient of the therapy, treatment or procedure, or any product made for such purpose.  The Field shall also exclude gene therapy or transgenics, or the production by gene therapy, or transgenic animals or transgenic plants, of recombinant Factor IX protein.

IPSCIO Record ID: 328345

License Grant
Generally, by this collaboration, Licensor shall optimize its Existing AsOR Targeted Complex by construction and improvement of plasmid vectors to obtain the required level and duration of Factor VIlI expression from the recombinant Factor VIlI constructs provided by Licensee.

Licensor grants an exclusive license, or in the case of licensed Third Party Patent Rights or Know-How, when permissible, an exclusive sublicense, in the Territory under Licensors Patent Rights, including Licensors rights in any jointly-owned Patent Rights, and Licensors Know How, to conduct the Collaborative Program and to make, use, sell, offer for sale, import, and have made, used, sold, and imported Products for use in the Hemophilia A Field and to each Additional Field(s) upon Licensees exercise of its option(s).

For the License Grant to Licensee Outside the Field(s), for sole inventions and knowhow made by Licensor during the term of and under the Research Program, which are Improvements in the coding and/or non-coding elements for optimizing and/or regulation of gene expression, Licensor grants a world-wide, non-exclusive,
including the right to grant sublicenses, to practice, make, use, sell, import and have practiced, made, used, sold and imported such Improvements for use outside the Field(s).

License Property
Licensor has certain technology regarding the delivery of human genes for use in the prevention and treatment of diseases, states and conditions in humans.

Alternate Ligand-Targeted Complex shall mean a molecular complex comprising a recombinant AsOR ligand or a non-plasma derived ligand such as, but not limited to, a synthetic carbohydrate ligand, said ligand having the ability to bind to the AsOR receptor and which is covalently linked to a polycation and noncovalently bound to DNA.

AsOR shall mean asialoorosomucoid.

Gene shall mean any one of the Factor VIII Gene or the Additional Gene(s), if any.  Factor VIII Gene shall mean cDNA for full-length human factor VIII or an engineered deletion or substitution constructs, including B-domain deleted constructs, hereinafter modified, of human factor VIII.

Additional Gene shall mean full length or truncated cDNA for a specific human blood coagulation factor, other than factor VIII, which the parties mutually agree to add to the Collaborative Program and the Agreement.

Field of Use
The collaboration agreement is for development gene therapy products for the treatment of hemophilia A, a hereditary blood clotting disorder.

Field shall mean any one of the Hemophilia A Field or the Additional Field(s), if any; or shall mean, collectively, the Hemophilia A Field and the Additional Field(s).

Additional Field shall mean, the treatment of any blood coagulation disorder in humans using Gene Delivery technology for targeting one or more Additional Gene into a mammalian cell of a patient.

IPSCIO Record ID: 299288

License Grant
The parties amend and replace the Original Agreement to separate the next generation recombinant coagulation Factor VIII into its own Agreement.  Licensor hereby grants, and agrees to grant, to Danish Licensee, as of the Original Date , the following rights and licenses

Exclusive License.  As of the Original Date, Licensor hereby grants, and agrees to grant, to Licensee an exclusive (even as to Licensor), royalty-bearing license in the Field of Use under the Licensor Intellectual Property used or required to be used in the Field of Use during the Term, (i) to conduct research, sample, develop (including clinical development), manufacture, make, use, market, promote, sell, offer for sale, have sold, distribute, import and export New Products in the Territory, and (ii) to use the Reagents in the Territory solely for the purpose of making New Products.

Limited Sublicense Rights Licensee shall be entitled to grant full sublicenses to its Affiliates and limited sublicenses to its distribution, marketing and/or sales partners, in each case, in compliance with this Agreement.

License Property
Licensor Patents means (a) all Patent Rights relating to methods and processes for glycosylation design and remodeling of proteins, peptides and antibodies that are  Controlled by Licensor, including, but not limited to the Patent Rights listed.
6,800,468 – UDP-galactose .beta.-N-acetyl-glucosamine .beta.1,3galactosyltransferases, .beta.3Gal-T5
6,995,004 – UDP-N-ACETYLGLUCOSAMINE GALACTOSE-.beta. 1,3-N-ACETYLGALACTOSAMINE-.alpha.-R / N-ACETYLGLUCOSAMINE-.beta. 1,3,-N-ACETYLGALACTOSAMINE-.alpha.-R (GLCNAC TO GALNAC) .beta.1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2/4GNT
6,635,461 – UDP-N-acetylglucosamine galactose-.beta.1, 3-N-acetylgalactosamine-.alpha.-R/(GlcNAc to GalNAc) .beta.1,6-N-acetylglucosaminyltransferase, C2GnT3

New Product shall mean the following (a) any of the Licensee Materials modified using either (i) the Licensor Technology, (ii) any Licensor Improvements, or (iii) any combination of all or some of (i) and (ii) above, and (b) any Licensee Materials covered by any Carved Factor VIII Claims (except to the extent such claims constitute Licensee Improvements).

M1 Profile for the New Factor VIII Product means the parameters for candidate selection required for PEG-F8.

Reagents means the enzymes and sugar nucleotides required to use the Licensor Technology in the manufacture of New Products.

Carved Factor VIII Claims shall mean any Potential Carved Factor VIII Claim with respect to which the parties have filed a separate patent application.

Potential Carved Factor VIII Claims shall mean any composition-of-matter claims and any method of treatment claims that are supported by Patent Rights Controlled by Licensor that (i) do or could explicitly and solely recite and claim Licensee Materials, or (ii) any Licensee Improvements made or reduced to practice by Licensor.

Product-Candidate means any new hemostasis product-candidate Controlled by Licensor during the Term.

Licensor Intellectual Property means Licensor Technology and the Licensor Improvements.

Licensor Technology means the Licensor Patents and any Know-How Controlled by Licensor relating to methods and processes for the glycosylation design and remodeling of proteins, peptides and antibodies, including, without limitation, its GlycoAdvance®, GlycoPEGylation™ and GlycoConjugation™ technologies, and other carbohydrate synthesis processes, and all Know-How resulting from work conducted by Licensor during the Term.

Licensor Improvements means any and all Improvements relating to the Licensor Technology made, conceived, or reduced to practice by (i) either Licensor or Licensee or both in the conduct of the Original Work Plan under the Original Agreement or the Work Plan under this Agreement, (ii) either Licensor or Licensee or both under this Agreement.

GlycoPEG-FVIIa is a long-acting form of recombinant Factor VIIa that is being developed by our partner, Novo Nordisk A/S, utilizing our GlycoPEGylation technology. Factor VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation Factors VIII or IX.

Field of Use
Licensee is also developing long-acting forms of recombinant Factor VIII and recombinant Factor IX utilizing our GlycoPEGylation technology. Factor VIII products are used in the treatment of Hemophilia A, and Factor IX products are used in the treatment of Hemophilia B.

IPSCIO Record ID: 335674

License Grant
Licensor granted Licensee an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by us for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Licensee granted Licensor a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Licensee to manufacture our products that utilize the AAV delivery system. During a specified period, neither Licensor nor Licensee are permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.

The parties are collaborating for a research, development and commercialization of giroctocogene fitelparvovec, also known as SB-525. Licensee is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec and Licensee is responsible for conducting the Phase 1/2 clinical study and certain manufacturing activities for giroctocogene fitelparvovec.

License Property
Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for hemophilia A, and closely related products such as Affine.

AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe hemophilia A. The primary endpoint is impact on annual bleed rate (ABR) through 12 months following treatment with giroctocogene fitelparvovec, compared to ABR on Factor VIII (FVIII) replacement therapy collected in the Phase 3 lead-in study period. Participants will be analyzed throughout the 5-year study period following the single infusion to further assess the durability and efficacy.

Field of Use
Field of use is for the gene therapy for the treatment of Hemophilia A.

Hemophilia is a medical condition in which the ability of the blood to clot is severely reduced, causing the sufferer to bleed severely from even a slight injury. The condition is typically caused by a hereditary lack of a coagulation factor, most often factor VIII.

IPSCIO Record ID: 234445

License Grant
Licensee today announced that it has expanded its existing clinical collaboration agreement with Japanese Licensor to develop AndexXaâ„¢ (andexanet alfa) as an antidote for edoxaban, Licensor's Factor Xa inhibitor.

The parties agreed to amend the agreement to expedite the expansion of our Phase 4 trial of Andexxa.  The original agreement was entered into to study the safety and efficacy of Andexxa as a reversal agent to edoxaban, in our Phase 3 and Phase 4 studies.  The Licensee is responsible for the cost of conducting these clinical studies. Pursuant to our agreement with Licensor, Licensee is obligated to provide research, development and regulatory services and to manufacture and supply Andexxa.

License Property
Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] is the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban.

AndexXa (andexanet alfa), an investigational drug, is a modified human Factor Xa molecule that acts as a decoy to target and sequester with high specificity both oral and injectable Factor Xa inhibitors in the blood. Once bound, the Factor Xa inhibitors are unable to bind to and inhibit native Factor Xa, thus potentially allowing for the restoration of normal hemostatic processes. AndexXa is the first compound being studied as an antidote for Factor Xa inhibitors that directly and specifically reverses anti-Factor Xa activity – the anticoagulant mechanism of these agents.

Field of Use
This agreement pertains to the drug industry relating to therapeutics in the areas of thrombosis, other hematologic disorders and inflammation.

Licensee is developing andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, for patients treated with a direct or indirect Factor Xa inhibitor when reversal of anticoagulation is needed, such as for life-threatening or uncontrolled bleeding or emergency surgery and urgent procedures.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.